|
EP3677259A1
|
|
Use of arachidonyl trifluoromethyl ketone
|
|
WO2013150132A2
|
|
Polypeptide markers for diagnosis and assessment of strokes
|
|
AU2013214292A1
|
|
Polypeptide markers for diagnosis and assessment of heart failure
|
|
WO2012123527A1
|
|
Method and markers for the diagnosis of subclinical and clinical forms of t-cell-mediated tubulointerstitial rejection after kidney transplantation
|
|
EP2649450A1
|
|
Method and marker for the diagnosis of a bile duct stricture and of a cholangiocellular carcinoma in bile
|
|
WO2011029954A2
|
|
Polypeptide marker for diagnosing and assessing vascular diseases
|
|
EP2449385A1
|
|
Method and markers for diagnosing acute renal failure
|
|
EP2394171A2
|
|
Autosomal dominant polycystic kidney disease (adpkd)
|
|
WO2010031822A1
|
|
Kidney cell carcinoma
|
|
AU2008309605A1
|
|
Polypeptide marker for the diagnosis of prostate cancer
|
|
ZA200806172B
|
|
Method and markers for the diagnosis of renal deseases
|
|
BRPI0808703A2
|
|
Process for Standardization of Component Concentration for Analysis in a Urine Sample
|
|
EP2051078A1
|
|
Method and marker for diagnosing diabetes mellitus
|
|
EP1972940A1
|
|
Method and marker for diagnosing kidney disease
|
|
CN101317095A
|
|
Polypeptide marker for the diagnosis and evaluation of vascular diseases
|
|
SG170009A1
|
|
Polypeptide markers for the diagnosis and evaluation of vascular diseases
|
|
WO2007000466A1
|
|
Polypeptide marker for detecting the rejection of transplanted kidneys at an early stage
|
|
AU2006231611A1
|
|
Polypeptide markers for the diagnosis of prostate cancer
|
|
EP1869473A2
|
|
Polypeptide marker for diagnosing alzheimer's disease
|
|
KR20080091234A
|
|
Method and markers for the diagnosis of renal diseases
|
